Research ExplorerPublicationsA Phase II study of selinexor plus cytarabine and idarubicin...

A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Standard

A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. / Fiedler, Walter; Chromik, Joerg; Amberg, Stefanie; Kebenko, Maxim; Thol, Felicitas; Schlipfenbacher, Vera; Christine Wilke, Anne; Modemann, Franziska; Janning, Melanie; Serve, Hubert; Ganser, Arnold; Bokemeyer, Carsten; Theile, Susann; Deppermann, Ute; Kranich, Anne L; Heuser, Michael.

In: BRIT J HAEMATOL, Vol. 190, No. 3, 08.2020, p. e169-e173.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Fiedler, W, Chromik, J, Amberg, S, Kebenko, M, Thol, F, Schlipfenbacher, V, Christine Wilke, A, Modemann, F, Janning, M, Serve, H, Ganser, A, Bokemeyer, C, Theile, S, Deppermann, U, Kranich, AL & Heuser, M 2020, 'A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia', BRIT J HAEMATOL, vol. 190, no. 3, pp. e169-e173. https://doi.org/10.1111/bjh.16804

APA

Fiedler, W., Chromik, J., Amberg, S., Kebenko, M., Thol, F., Schlipfenbacher, V., Christine Wilke, A., Modemann, F., Janning, M., Serve, H., Ganser, A., Bokemeyer, C., Theile, S., Deppermann, U., Kranich, A. L., & Heuser, M. (2020). A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. BRIT J HAEMATOL, 190(3), e169-e173. https://doi.org/10.1111/bjh.16804

Vancouver

Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V et al. A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. BRIT J HAEMATOL. 2020 Aug;190(3):e169-e173. https://doi.org/10.1111/bjh.16804

Bibtex

@article{e30c8651fd3e4f7989243e517835e6e3,
title = "A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia",
author = "Walter Fiedler and Joerg Chromik and Stefanie Amberg and Maxim Kebenko and Felicitas Thol and Vera Schlipfenbacher and {Christine Wilke}, Anne and Franziska Modemann and Melanie Janning and Hubert Serve and Arnold Ganser and Carsten Bokemeyer and Susann Theile and Ute Deppermann and Kranich, {Anne L} and Michael Heuser",
year = "2020",
month = aug,
doi = "10.1111/bjh.16804",
language = "English",
volume = "190",
pages = "e169--e173",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

AU - Fiedler, Walter

AU - Chromik, Joerg

AU - Amberg, Stefanie

AU - Kebenko, Maxim

AU - Thol, Felicitas

AU - Schlipfenbacher, Vera

AU - Christine Wilke, Anne

AU - Modemann, Franziska

AU - Janning, Melanie

AU - Serve, Hubert

AU - Ganser, Arnold

AU - Bokemeyer, Carsten

AU - Theile, Susann

AU - Deppermann, Ute

AU - Kranich, Anne L

AU - Heuser, Michael

PY - 2020/8

Y1 - 2020/8

U2 - 10.1111/bjh.16804

DO - 10.1111/bjh.16804

M3 - Other (editorial matter etc.)

C2 - 32515072

VL - 190

SP - e169-e173

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 3

ER -